TABLE 4.
Literature Review of Prior Reports of Pathologic Complete Response in Pancreatic Cancer Following Neoadjuvant Therapy
| Reference | Institute (Country) | Inclusion Period | Resectability Status of Tumor | Neoadjuvant Regimen | % pCR | Recurrence and Survival Status of Patients With pCR |
|---|---|---|---|---|---|---|
| Snady et al (2000)25 | Mt. Sinai NY (USA) | 1989–1997 | 68 LAPC | CHT: 5-FU/Cisplatin RT: 54 Gy | 3/20 (15%) | NR |
| Calvo et al (2004)26 | Hospital G. Maranon (Spain) | 1998–2001 | 15 resectable | CHT: Tegafur RT: 45 −50.4 Gy | 3/9 (33%) | 3 pt alive with NED at 9. 25 and 36 mos. |
| Moutardier et al (2004)11 | Paoli-Calmettes (France) | 1996–2003 | 61 resectable | CHT: 5-FU/Cisplatin RT: 30–45 Gy | 3/40 (8%) | 1 pt died with liver mets at 27 mos. 2 pt alive with NED at 12 and 66 mos. |
| Turrini et al (2009)27 | Paoli-Calmettes (France) | 1996–2007 | 102 resectable | CHT: 5-FU/Cisplatin RT: 45 Gy | 8/62 (13%) | NR |
| White et al (2005)28 | Duke University (USA) | 1994–2005 | 51 BR + 16 LAPC | CHT: 5-FU RT: 30–45 Gy | 4/54* (7%) | 2 pt died of progression at 22 and 29 mos. 2 pt died with NED at 11 and 16 mos. |
| Katz et al (2008)29 | MD Anderson CC (USA) | 1999–2006 | 125 BR | CHT: multiple RT: 30–50.4 Gy | 4/66 (6%) | 1 pt developed mets. 1 pt died of lung cancer. 2 pt alive with NED |
| Chatterjee et al (2012)9 | MD Anderson CC (USA) | NR | NR | CHT: multiple RT: 30–50.4 Gy | 6/223 (3%) | 6 pt alive with NED. |
| Zhao et al (2012)10 | MD Anderson CC (USA) | 1995–2010 | NR | CHT: multiple RT: 30–50.4 Gy | 11/442 (3%) | 6 pt alive with NED at 10–194 mos (median 63). 3 pt died of other causes. 1 pt with 2nd primary PDAC at 84 mo† |
| Lee et al (2016)24 | MD Anderson CC (USA) | 2008–2012 | NR | CHT: multiple RT: 30–50.4 Gy | 3/167 (2%) | 3 pt alive with NED. |
| Cloyd et al (2017)30 | MD Anderson CC (USA) | 1990–2015 | NR | CHT: multiple RT: 30–50.4 Gy | 23/583 (4%) | 81 mos median survival for all pt. 4 pt developed distant recurrence |
| Tinkl et al (2009)31 | F. Alexander Univ. (Germany) | 1996–2006 | 120 LAPC | CHT: 5-FU or Gem/Cis RT: 50.4–55.8 Gy | 3/38 (8%) | NR |
| Chun et al (2011)12 | Fox Chase Center (USA) | 1987–2009 | NR | CHT: multiple RT: 50.4 Gy | 8/107 (7%) | NR |
| Rajagpalan et al (2013)32 | Univ. of Pittsburgh (USA) | 2008–2011 | 7 BR + 5 LAPC | CHT: multiple SBRT: 24–46 Gy | 3/12 (25%) | NR |
| Rose et al (2014)33 | VA Mason MC (USA) | 2008–2012 | 64 BR | CHT: Gem/Docetaxel RT: 50.4 Gy | 3/31 (10%) | NR |
| Pietrasz et al (2015)22 | AGEO-FRENCH cohort (France) | 2010–2013 | 47 BR + 33 LAPC | CHT: FFX RT: 54 Gy | 12/80 (15%) | NR |
| Hirata et al (2015)34 | Osaka Medical Center (Japan) | 2006–2011 | 104 resectable + 53 BR | CHT: Gem alone RT: 50 Gy | 6/157 (4%) | NR |
| Lee et al (2015)35 | Yonsei Univ. (South-Korea) | 2000–2012 | 35 resectable + 28 BR + 14 LAPC | CHT: Gem-based RT: 50–60 Gy | 9/86 (10%) | 4 pt with recurrence (2 liver. 2 peritoneum) and 5 pt alive with NED at 10–63 mos (median 21 mos) |
| Chuong et al (2016)13 | Univ. of Maryland (USA) | 2009–2012 | 36 BR | CHT: GTX RT: 32.5–40 Gy | 4/36 (11%) | 4 pt alive with NED |
| Rashid et al (2016)36 | Mofitt Cancer Center (USA) | 2006–2013 | 94 BR | CHT: GTX SBRT: 30–40 Gy | 10/55 (18%) | NR |
| Hashemi-Sadraei et al (2017)23 | Indiana University (USA) | 2008–2014 | 53 BR/LAPC | CHT: multiple RT: 45–54 Gy | 6/53 (11%) | 2 pt died (median 11 mos), 4 pt alive median survival 28.7 mos. 3 of which have recurred at median 20.4 mos |
| Mellon et al (2017)37 | Mofitt Cancer Center (USA) | 2010–2015 | 8 LAPC + 73 BR | CHT: multiple SBRT: 30–50 Gy | 6/81 (7%) | 6 pt alive with NED at median 33 mos. including 1 pt with liver met at 7 mos. treated with RFA and FFX. alive with NED at 27 mos. |
*
54/70 specimens available for examination.
†
Follow-up data available for 10/11 patients with pathologic complete response.
5-FU indicates 5-flourouracil; BR, borderline resectable; CHT, chemotherapy; FFX, FOLFIRINOX; Gem, gemcitabine; GTX, gemcitabine, docetaxel, and capecitabine; Gy, Gray; LAPC, locally advanced unresectable disease; mos; months; NR, not reported; pCR, pathologic complete response; pt, patient; RT, radiotherapy.